Wire · opportunities
Hims & Hers Health (HIMS) Adds FDA Approved Obesity Drugs To Its Platform
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 7 November 2026 · Fusion42 review
Hims & Hers Health has partnered with Eli Lilly to offer FDA-approved GLP-1 obesity drugs Zepbound and Foundayo through its telehealth platform, enhancing access to regulated obesity treatments for eligible patients in the US. The partnership may affect Hims & Hers Health's subscriber dynamics and regulatory scrutiny due to defined pricing models for these branded drugs.
This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure, and 5 sources have reported it between 6 Nov 2026 and 8 Nov 2026.
◆ ◆ The Wire takeaway
You gain new revenue channels through fully FDA-approved obesity drugs integrated in telehealth, shifting your subscriber mix and regulatory focus this quarter. Track Hims & Hers' weight loss member disclosure to see if branded drugs actually grow or just replace existing programs.
◆ Coverage
5 sources · first reported 6 Nov 2026 · latest 8 Nov 2026
◆ Related on Wire
◆ Topics